AZD9291 First Time In Patients Ascending Dose Study
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study will treat patients with advanced NSCLC who have already received at least one
course of specific anti-cancer treatment but the tumour has started to re-grow following that
treatment. This is the first time this drug has ever been tested in patients, and so it will
help to understand what type of side effects may occur with the drug treatment, it will
measure the levels of drug in the body, it will also measure the anti-cancer activity. By
using these pieces of information together the best dose of this drug to use in further
clinical trials will be selected.